Current and historical daily PE Ratio for Apollon Formularies PLC (
) from 1990 to May 31 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Apollon Formularies PLC stock (AQSE:APOL) PE ratio as of May 31 2024 is 0.
More Details
Apollon Formularies PLC (AQSE:APOL) PE Ratio (TTM) Chart
Apollon Formularies PLC (AQSE:APOL) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1150
- 1
- 2
- 3
- 4
- 5
- 6
- 13
| Apollon Formularies PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-01 | At Loss | 2024-03-26 | At Loss |
| 2024-05-30 | At Loss | 2024-03-25 | At Loss |
| 2024-05-29 | At Loss | 2024-03-22 | At Loss |
| 2024-05-28 | At Loss | 2024-03-21 | At Loss |
| 2024-05-24 | At Loss | 2024-03-20 | At Loss |
| 2024-05-23 | At Loss | 2024-03-19 | At Loss |
| 2024-05-22 | At Loss | 2024-03-18 | At Loss |
| 2024-05-21 | At Loss | 2024-03-15 | At Loss |
| 2024-05-20 | At Loss | 2024-03-14 | At Loss |
| 2024-05-17 | At Loss | 2024-03-13 | At Loss |
| 2024-05-16 | At Loss | 2024-03-12 | At Loss |
| 2024-05-15 | At Loss | 2024-03-11 | At Loss |
| 2024-05-14 | At Loss | 2024-03-08 | At Loss |
| 2024-05-13 | At Loss | 2024-03-07 | At Loss |
| 2024-05-10 | At Loss | 2024-03-06 | At Loss |
| 2024-05-09 | At Loss | 2024-03-05 | At Loss |
| 2024-05-08 | At Loss | 2024-03-04 | At Loss |
| 2024-05-07 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-19 | At Loss |
| 2024-04-22 | At Loss | 2024-02-16 | At Loss |
| 2024-04-19 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-09 | At Loss |
| 2024-04-12 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
| 2024-04-08 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
Apollon Formularies PLC (AQSE:APOL) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Apollon Formularies PLC
ISIN : IM00BJ0LRD77
Description
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers